Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Other Working Capital Changes: 2009-2025

Historic Other Working Capital Changes for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $1.0 million.

  • BIO-TECHNE's Other Working Capital Changes fell 68.30% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 227.30%. This contributed to the annual value of $14.4 million for FY2025, which is 356.83% up from last year.
  • BIO-TECHNE's Other Working Capital Changes amounted to $1.0 million in Q3 2025, which was down 86.01% from $7.2 million recorded in Q2 2025.
  • BIO-TECHNE's Other Working Capital Changes' 5-year high stood at $7.2 million during Q2 2025, with a 5-year trough of -$3.4 million in Q1 2022.
  • In the last 3 years, BIO-TECHNE's Other Working Capital Changes had a median value of $1.2 million in 2024 and averaged $1.9 million.
  • Per our database at Business Quant, BIO-TECHNE's Other Working Capital Changes plummeted by 577.12% in 2024 and then skyrocketed by 684.22% in 2025.
  • Quarterly analysis of 5 years shows BIO-TECHNE's Other Working Capital Changes stood at $1.2 million in 2021, then plummeted by 164.36% to -$755,000 in 2022, then soared by 176.42% to $577,000 in 2023, then slumped by 577.12% to -$2.8 million in 2024, then slumped by 68.30% to $1.0 million in 2025.
  • Its Other Working Capital Changes stands at $1.0 million for Q3 2025, versus $7.2 million for Q2 2025 and $6.8 million for Q1 2025.